Meeting
2016 ASCO Annual Meeting
A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.
Authors
May Thet Cho
City of Hope, Duarte, CA
May Thet Cho , Dean Lim , Timothy W. Synold , Paul Henry Frankel , Lucille A. Leong , Joseph Chao , Vincent M. Chung , Yuan Chen , Stephen Sentovich , Eloise Luevanos , Marwan Fakih
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Other Novel Agents
Clinical Trial Registration Number
NCT02041481
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2544)
DOI
10.1200/JCO.2016.34.15_suppl.2544
Abstract #
2544
Poster Bd #
244
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
A phase I study of MEK162 and FOLFOX in chemotherapy-resistant metastatic colorectal cancer.
First Author: May Thet Cho
Poster
2012 Gastrointestinal Cancers Symposium
Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on first-line oxaliplatin-based chemotherapy.
First Author: Li-Tzong Chen
Poster
2023 ASCO Annual Meeting
A phase 1/2a, multicenter, open-label study of CNA3103 (LGR5-targeted, autologous CAR-T cells) in patients with metastatic colorectal cancer (mCRC).
First Author: Jayesh Desai
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase I study of pharmacokinetic (PK)-driven sequential dosing of rucaparib (RUB) with irinotecan liposome (nal-IRI) and fluorouracil (5FU) in metastatic gastrointestinal (mGI) and pancreas (PANC) cancers.
First Author: Wen Wee Ma